Mitigating the Fall: Profitability Beyond the Blockbuster

Branded pharma strategizes to stay profitable despite expiring patents

PM1605 WebLeadImage 295X269

Even though the pharmaceutical industry is approaching what most analysts say is the tail end of the patent cliff tumble, the industry is still under pressure to develop strategies to stay profitable in what looks to be a new, non-blockbuster-reliant era. In the shrinking window between market approval and patent expiration, pharmaceutical companies are coming face to face with the stark realties of revenue erosion. In the United States and Europe, generics — strongly incentivized by payer initiatives — are here to stay, making the strategies brand pharmaceutical companies employ both before and after patent expiration imperative to fiscal survival. In worst-case…

Full Story

Don't Miss These Pharma Manufacturing Exclusives

Fundamentals

On-demand, concise audio and powerpoint tutorials on the fundamental concepts of pharmaceutical manufacturing, process development, quality control and compliance.

Ask the Expert

We've assembled a roster of leading authorities in many fields to help you address technical issues. Pose a question or browse previous questions to find helpful answers.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Mitigating the Fall: Profitability Beyond the Blockbuster

    By Karen Langhauser, Chief Content Director

    Even though the pharmaceutical industry is approaching what most analysts say is the tail end of the patent cliff tumble, the industry is still under pressure to develop strategies to stay profitable in what looks to be a new, non-blockbuster-reliant era. In the shrinking window between market…

    Full Story
  • Stop Feeding Customers Cardboard Pizza

    By Karen Langhauser, Chief Content Director

    I consider myself a connoisseur of late-night pizza. With this prestigious distinction comes a fair amount of interest in the happenings of popular pizza chains (as well as a fair amount of weight gain). My favorite sales and marketing turnaround story is Domino’s Pizza. Faced with more than two…

    Full Story
  • The Rise & Diversification of Biologics

    By Evolution Global

    A team from Evolution Global analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and diversification of biologics. From start-ups to blue chips, they evaluated the pharmaceutical players involved in the ongoing…

    Full Story
  • PLM for Pharma: Applying an Old Tool in New Ways

    By Chris Albani, Vitaly Glozman, Wayne McDonnell, Shankar Iyer and Yun Wakana Wang, PwC

    Dr. Smith — the development lead for her company’s most promising new drug product — has been losing sleep over the past month pulling together the CMC (Chemistry, Manufacturing and Control) section of the regulatory submission. The compound has shown excellent efficacy and safety data, and…

    Full Story
  • Paradise Lost

    By James Agalloco, Agalloco & Associates

    When isolators were introduced into the pharmaceutical industry they were properly viewed with some degree of skepticism. The early designs were relatively crude in appearance and certainly lacked sophistication. With a few years of technology development and successful operational experience it…

    Full Story
  • Replicating Success: Scaling Up Quality Transformation

    By Sasikanth Dola, Jean-Baptiste Pelletier, Lorenzo Positano and Paul Rutten, McKinsey & Company

    Transforming quality in an entire organization that comprises thousands of production steps and employees and tens of thousands of SKUs is one of the most difficult challenges for any pharmaceutical company. By nature, every pharmaceutical product is unique, which means its production process…

    Full Story

Latest Products